Michael Hofman
Led proPSMA and TheraP, the trials that proved PSMA PET beats conventional imaging and that lutetium-PSMA beats chemotherapy.
Overview
Michael Hofman is Professor of Nuclear Medicine and Director of the Prostate Cancer Theranostics and Imaging Centre of Excellence at the Peter MacCallum Cancer Centre in Melbourne. He led proPSMA, which proved that PSMA PET-CT beats conventional imaging for staging high-risk prostate cancer before curative-intent surgery or radiotherapy, and TheraP, the ANZUP trial that showed lutetium-177 PSMA-617 beats cabazitaxel chemotherapy in metastatic castration-resistant prostate cancer. His publications include the proPSMA and TheraP reports, and his trials made Australia a global centre of theranostics. He now leads trials of earlier-line and combination radioligand therapy.
For men whose prostate cancer has grown after chemotherapy, a PSMA-targeted radioactive treatment worked at least as well as, and was gentler than, the chemotherapy drug it replaced - provided a PET scan first confirms the cancer takes up the PSMA tracer.
In a small early trial, most heavily pre-treated men with advanced prostate cancer responded to the PSMA-targeted radioactive drug, with manageable side effects, supporting the case for testing it in larger randomised trials.
Similar pages
not linked directly; found by shared links- PersonShahneen Sandhu
Shares ANZUP Cancer Trials Group, Peter MacCallum Cancer Centre, TheraP: [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer, PSMA.
- PersonDeclan G. Murphy
Shares proPSMA, ANZUP Cancer Trials Group, Peter MacCallum Cancer Centre, PSMA.
- PersonLouise Emmett
Shares TheraP: [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer, PSMA, Lutetium-177 vipivotide tetraxetan, PSMA PET.
- PersonMichael J. Morris
Shares TheraP: [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer, PSMA theranostics roadmap: antigen discovery → PSMA PET → 177Lu-PSMA-617 → earlier lines and alpha, PSMA, Lutetium-177 vipivotide tetraxetan.
- PersonRahul Aggarwal
Shares PSMA, Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters).
- PersonJohannes Czernin
Shares PSMA, Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters).
- PersonRodney J. Hicks
Shares proPSMA, Peter MacCallum Cancer Centre, Lutetium-177 vipivotide tetraxetan, Lutetium-177.
- PersonUwe Haberkorn
Shares A university cyclotron network with shared regulatory files for new tracers, PSMA theranostics roadmap: antigen discovery → PSMA PET → 177Lu-PSMA-617 → earlier lines and alpha, PSMA, Lutetium-177 vipivotide tetraxetan.